The PROMIS of Precision Amyloid Oligomer Targeting: Initiating OW

Research evidence excerpt

The PROMIS of Precision Amyloid Oligomer Targeting: Initiating OW

June 29, 2026

PMN Investment Summary

ProMIS is a CNS/neurodegenerative disease focused biotech, not on most investors’ radar.

• PMN uses its EpiSelect Platform to design mAbs & vaccines that selectively recognize toxic misfolded proteins to slow/halt disease progression.

We see PMN shares as attractive for the following reasons:

1. Lead asset PMN310 (Fast Track) is an anti-Aβ mAb being developed for Alzheimer’s disease (AD) with properties that may drive a differentiated

efficacy & safety profile vs approved Aβ mAbs lecanemab & donanemab

• PMN310 has a distinct binding profile vs approved/failed Aβ mAbs it’s highly selective for Aβ oligomers (AβOs) vs monomers, fibrils, & plaque.

o A wealth of scientific data suggest that AβOs may be a key neurotoxic Aβ species that drives Alzheimer's progression if the case, PMN310 may

show a differentiated efficacy profile vs approved Aβ mAbs.

o Preclinical data show that PMN310 does not bind to Aβ plaque it may lead to differentiated safety profile with ARIA rates in line with pbo.

2. P1b data readout may act as near-term value driver.

• 6-month blinded interim P1b PRECISE-AD biomarker & safety (ARIA) data in 3Q26 – could increase confidence in a positive 12-month readout.

• 12-month data in 1Q27 – if positive, could drive significant upside to current trading levels.

3. Early-stage neurodegenerative focused pipeline represents free call options, in our view.

• These programs are high-risk/reward, which little to no credit being given – they represent upside to our explicit projections. They include:

o mAb based assets targeting TDP-43 for ALS & FTD, & α-synuclein for Parkinson’s, MSA, & DLB.

o Vaccines for ALS, FTD, MSA, Aβ & α-synuclein.